CLDI Stock Summary and Trading Ideas (Calidi Biotherapeutics | AMEX:CLDI)

Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.

Calidi Biotherapeutics trades on the AMEX stock market under the symbol CLDI.

As of March 13, 2026, CLDI stock price declined to $0.32 with 201,761 million shares trading.

CLDI has a beta of 1.16, meaning it tends to be more sensitive to market movements. CLDI has a correlation of 0.01 to the broad based SPY ETF.

CLDI has a market cap of $2.28 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that CLDI belongs to (by Net Assets): VXF.

CLDI has underperformed the market in the last year with a price return of -96.7% while the SPY ETF gained +19.8%. CLDI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -78.2% and -62.4%, respectively, while the SPY returned -2.6% and -3.9%, respectively.

CLDI support price is $.30 and resistance is $.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLDI shares will trade within this expected range on the day.